Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D5BP | ISIN: US28258A1079 | Ticker-Symbol: EIIA
Siehe auch EISAI CO LTD
Frankfurt
01.04.25
15:29 Uhr
6,000 Euro
-0,050
-0,83 %
Branche
Pharma
Aktienmarkt
JAPAN
1-Jahres-Chart
EISAI CO LTD ADR Chart 1 Jahr
5-Tage-Chart
EISAI CO LTD ADR 5-Tage-Chart

Aktuelle News zur EISAI CO LTD ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:34Eisai to Divest Rights for Pariet in China to Peak Pharma199TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in...
► Artikel lesen
SoEisai Aktie: Schicksalhafte Unsicherheit?492Die Eisai-Aktie bleibt unter Druck und setzte am Freitag ihren Abwärtstrend fort. Mit einem Kursverlust von 1,76 Prozent schloss der Titel bei 26,26 Euro und markierte damit einen Wochenverlust von...
► Artikel lesen
FrLilly hits same Alzheimer's roadblock in Europe as Eisai, Biogen 19
25.03.Eisai lays out road map to blockbuster sales projections for Leqembi's 'milestone' 2027 year5
EISAI CO LTD ADR Aktie jetzt für 0€ handeln
25.03.Eisai: World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Awardat the 12th Technology Management and Innovation Awards307TOKYO, Mar 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aß) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early...
► Artikel lesen
25.03.Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace207TOKYO, Mar 25, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko...
► Artikel lesen
25.03.BioArctic's partner Eisai presents sales simulation for Leqembi at its annual press conference245STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales...
► Artikel lesen
21.03.Eisai's abandoned Enhertu challenger set to live on at BlissBio3
21.03.Angle PLC Announces Results of Eisai Phase 2 pilot study201UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACTDevelopment of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay...
► Artikel lesen
17.03.Eisai to buy "dementia ecosystem" partner EcoNaviSta7
10.03.Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time267TOKYO, Mar 10, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI)...
► Artikel lesen
06.03.In UK, it's strike 2 for Alzheimer's treatments from Lilly and Biogen/Eisai34
05.03.Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan468TOKYO, Mar 5, 2025 - (JCN Newswire) - Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding...
► Artikel lesen
04.03.Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia321TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision...
► Artikel lesen
03.03."Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"255- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine -TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell"...
► Artikel lesen
03.03.Eisai: The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease321TOKYO and CAMBRIDGE, Mass., Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
► Artikel lesen
28.02.Eisai, Biogen's Leqembi emerges from safety reappraisal unscathed as Europe's CHMP endorses slate of new drugs and label expansions8
28.02.Eisai Licenses Tasurgratinib to SciClone in Greater China Region3
28.02.Biogen, Eisai Alzheimer's drug sent back for EU nod after safety review17
28.02.BioArctic AB's Partner Eisai Says EU's CHMP Reaaffirms Positive Opinion For Lecanemab462WESTON (dpa-AFX) - Japanese pharmaceutical company Eisai Co. Ltd. (ESALF.PK), a partner of BioArctic AB (publ) (BRCTF.PK), Friday announced that the Committee for Medicinal Products for Human...
► Artikel lesen
Seite:  Weiter >>
146 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1